Analyst consensus rating
SAB Biotherapeutics Analyst Rating: Strong Buy
SABS is rated Strong Buy by 11 analysts with a $11.64 target. As of 2026-08-24.
Direct answer
SAB Biotherapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.64.
Forecast evidence checked August 24, 2026.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.69
- Average price target
- $11.64
- High price target
- $16.00
- Low price target
- $6.00
- Low target gap
- +62.8%
- Target upside
- +215.8%
- High target gap
- +334.2%
- Target range width
- 271.4%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for SAB Biotherapeutics?
SAB Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $11.64.
How far are SAB Biotherapeutics's low and high targets from the recorded price?
The low target implies +62.8%, while the high target implies +334.2%.
How many analysts are included in SAB Biotherapeutics's consensus?
The verified consensus includes 11 analysts.
How is SAB Biotherapeutics's target upside or downside calculated?
The average target of $11.64 is divided by the recorded price of $3.69, then one is subtracted to produce +215.8%. This does not guarantee a future return.
When was SAB Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.